Polymorphic markers of the LSR gene
AssigneeSerono Genetics Institute S.A.
InventorsMarta Blumenfeld, Lydie Bougueleret, Bernard Bihain
Life of this patent
Estimating the term…
Abstract
The invention provides novel LSR genomic sequences, polypeptides, antibodies, and polynucleotides including biallelic markers derived from the LSR locus. Primers hybridizing to regions flanking these biallelic markers are also provided. This invention also provides polynucleotides and methods suitable for genotyping a nucleic acid containing sample for one or more biallelic markers of the invention. Further, the invention provides methods to detect a statistical correlation between a biallelic marker allele and a phenotype and/or between a biallelic marker haplotype and a phenotype.
Claims16
A method for determining whether an individual is at risk of developing a detectable trait or whether a detectable trait that an individual suffers from is statistically associated with one or more LSR biallelic markers, comprising:
- obtaining a nucleic acid sample from said individual;
- and
- determining the identity of the polymorphic base of said one or more LSR biallelic marker in said nucleic acid sample;
- wherein the detectable trait is obesity or an obesity-related metabolic disorder;
- and wherein the LSR biallelic marker is selected from SNP #1 (A15;
- position 3778 of SEQ ID NO:
- 1), SNP #2 (A17;
- position 15007 of SEQ ID NO:
- 1), SNP #3 (A21;
- position 19744 of SEQ ID NO:
- 1) or SNP #4 (A30;
- position 359 of SEQ ID NO:
- 12).
A method of using an anti-obesity drug, comprising:
- obtaining a nucleic acid sample from an individual;
- determining the identity of a polymorphic base of one or more LSR biallelic markers selected from SNP #1 (A15;
- position 3778 of SEQ ID NO:
- 1), SNP #2 (A17;
- position 15007 of SEQ ID NO:
- 1), SNP #3 (A21;
- position 19744 of SEQ ID NO:
- 1) or SNP #4 (A30;
- position 359 of SEQ ID NO:
- 12) in said nucleic acid sample;
- and
- administering said drug to said individual if the genotype of SNP #1 is CT or TT and/or SNP #2 is AA and/or SNP #3 is GG.
A method of screening an individual for inclusion in a clinical trial of an anti-obesity drug comprising:
- obtaining a nucleic acid sample from said individual;
- determining the identity of the polymorphic base of one or more LSR biallelic markers selected from SNP #1 (A15;
- position 3778 of SEQ ID NO:
- 1), SNP #2 (A17;
- position 15007 of SEQ ID NO:
- 1), SNP #3 (A21;
- position 19744 of SEQ ID NO:
- 1) or SNP #4 (A30;
- position 359 of SEQ ID NO:
- 12) in said nucleic acid sample;
- and
- including said individual in said clinical trial if the genotype of SNP #1 is CT or TT and/or SNP #2 is AA and/or SNP #3 is GG.
Dependencies are inferred from the claim text.